Bendeka sales and marketing update

Teva and Eagle said CMS issued a J-code, effective Jan. 1, for Bendeka bendamustine. The drug is marketed in the U.S. to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin lympho...